Dupixent Lawsuit
Patients are pursuing legal claims alleging that Dupixent (dupilumab)—a biologic used to treat eczema, asthma, and nasal polyps—may be linked to the development or masking of cutaneous T-cell lymphoma (CTCL), a rare type of Non-Hodgkin’s Lymphoma (NHL).
Key CTCL subtypes involved include Mycosis Fungoides and Sézary Syndrome.
Lawsuits focus on whether the manufacturer provided sufficient warnings and whether CTCL symptoms were misdiagnosed as eczema, potentially delaying proper diagnosis and treatment.
Dupixent Class Action Lawsuit Guide: CTCL Risks, Eligibility & How to File
This guide outlines who may be eligible to file a claim, the evidence supporting these lawsuits, factors that could affect potential settlements, the latest updates in ongoing litigation, and a step-by-step overview of the legal process.
Who May Be Eligible for a Dupixent Lawsuit
- Treated with Dupixent (dupilumab) for 30 days or longer and later diagnosed with CTCL (a type of Non-Hodgkin’s Lymphoma) or a key CTCL subtype such as Mycosis Fungoides or Sézary Syndrome.
- Medical records confirm a CTCL diagnosis or document worsening skin symptoms while on Dupixent therapy.
- Cases where CTCL may have been misdiagnosed as eczema, resulting in delayed detection and treatment of lymphoma.
See if you qualify — free & confidential.
CTCL Symptoms & Warning Signs
- Persistent or worsening patches or plaques that resemble eczema or psoriasis
- Changes despite treatment, such as expanding lesions, color changes, or new nodules
- Itching, scaling, or skin pain that does not improve with standard therapies
- Advanced signs: development of tumors, swollen lymph nodes, or other systemic symptoms
If CTCL—including Mycosis Fungoides or Sézary Syndrome—is suspected, speak with your dermatologist about getting a skin biopsy with immunophenotyping.
Evidence That Can Support Your Dupixent Lawsuit
- Dermatology records: Progress notes, lesion maps, and photographs
- Pathology and biopsy reports: Including immunohistochemistry and T-cell receptor studies
- Medication history: Dupixent start/stop dates, dosage, and treatment response
- Differential diagnosis notes: Documentation showing suspected versus confirmed CTCL
- Impact records: Evidence of work limitations, treatment expenses, and specialist referrals
Potential Dupixent Settlements & Influencing Factors
- Strength of liability: Evidence regarding warnings, timing, and expert testimony
- Medical severity: CTCL stage or subtype, need for systemic treatment, and long-term health impacts
- Damages incurred: Medical expenses, lost income, pain and suffering, and anticipated future care
- Court and jury trends: Some jurisdictions may award higher damages in cases involving oncology-related conditions
This information is for educational purposes only and does not guarantee any outcome. Case values are based on reported verdicts and settlements. See sources below.
Dupixent Lawsuit Updates – December 2025
- Recent filings: New Dupixent–CTCL claims, including Mycosis Fungoides and Sézary Syndrome, allege delayed diagnosis due to symptoms being mistaken for eczema.
- Ongoing review: Cases are assessing whether internal safety reports and pharmacovigilance data should have prompted earlier warnings.
- Causation analysis: Dermatology and hematopathology experts are examining biopsy timelines and disease progression while patients were on treatment.
We provide monthly updates on MDL activity, notable case filings, and recent verdicts.
Understanding the Dupixent Lawsuit Process
- Free Case Evaluation: Provide your dermatology and pathology records, along with your treatment history.
- Investigation: Attorneys review your medical evidence and consult with experts to assess the claim.
- Filing: The lawsuit is submitted in the appropriate court; cases may be coordinated with related claims.
- Discovery & Negotiation: Both sides exchange evidence and may explore settlements or mediation.
- Resolution: The case is resolved through a settlement or trial, depending on the circumstances and jurisdiction.
Start your free claim review — no upfront fees.
FAQs
CTCL is a rare form of Non-Hodgkin’s Lymphoma (NHL) that mainly affects the skin. Common subtypes include Mycosis Fungoides and Sézary Syndrome. In its early stages, CTCL can resemble eczema or psoriasis, which may lead to delayed diagnosis.
Some lawsuits claim that Dupixent exposure may have contributed to the development or unmasking of CTCL (including Mycosis Fungoides and Sézary Syndrome), with symptoms often mistaken for eczema, delaying proper diagnosis.
Eligibility typically depends on medical documentation, timing, and expert analysis. An attorney can help assess causation, potential damages, and whether you have a viable claim.
Most cases are handled on contingency — no upfront fees; attorneys are paid only if they recover money for you.
Timeline Overview: Some cases may settle in just a few months through negotiation, while others could take a year or longer, depending on the complexity of discovery and the court’s location.
Sources
">
">
">
">
">
">
">
">
">
">
Check If You Qualify For Significant CompensationStart Your Claim Now
Determining your eligibility and securing the compensation you’re entitled to can be a complex process. A single misstep or poorly timed statement can jeopardize your claim. That’s why it’s critical to work with proven experts who understand the system and can guide you through every step – ensuring nothing is overlooked and every dollar you’re owed is pursued.
See If You Qualify for Compensation Quickly
Start Your Claim